Events Genome Engineering: CRISPR Frontiers 2025

Genome Engineering: CRISPR Frontiers

August 12-15, 2025

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Foster creative interactions between researchers interested in applying these systems to genome engineering and related advances in a wide variety of organisms, together with scientists studying the basic biology of CRISPR-Cas and related bacterial defense systems.

You're Invited to a MaxCyte Luncheon Seminar at Genome Engineering: CRISPR Frontiers 2025

Note: You must register for the Cold Spring Harbor Conference, Genome Engineering: CRISPR Frontiers to attend the workshop

Date: Wednesday, August 13, 2025
Time: Immediately following the morning session<
Location: Cold Spring Harbor Laboratory – Hershey Building (Upstairs)

Empowering Gene Editing Workflows: Real-Time Electroporation & Off-Target Analysis

Join us for a dynamic lunch-hour workshop designed for gene editing researchers eager to explore the latest in non-viral delivery and precision genome engineering. This session features a live demonstration of the MaxCyte® platform, showcasing its high-performance electroporation technology, followed by a scientific presentation on SeQure DX™, our advanced analytics solution for off-target detection and genome integrity assessment.

Led by our expert scientists, this session will:

  • Demonstrate real-time transfection using the MaxCyte system

  • Highlight how SeQure DX enables confident decision-making through sensitive, scalable off-target analysis

  • Provide insights into how these technologies work together to accelerate therapeutic development

Whether you're optimizing CRISPR workflows or scaling up for clinical manufacturing, this workshop will offer practical takeaways and live data to support your gene editing programs.

Lunch will be provided. Seating is limited—reserve your spot early!

Speakers

Nitin Kulkarni

Nitin Kulkarni, PhD

Senior Field Application Scientist, MaxCyte, Inc.

Nitin Kulkarni is a Sr. Field Application Scientist with MaxCyte, Inc. has been in scientific and field application support roles for over 10 years serving areas of Cell and Gene Therapy, 2D and 3D Cell Culture technologies, Molecular Biology, Immunology, Bioprocessing and Cell Isolation Technologies. Nitin completed his post-doctoral research evaluating the roles of mast cells in autoimmune diseases and cancer at Harvard Medical School’s Beth Israel Deaconess Medical Center in Boston, MA. He has worked with Corning Life Sciences and MicroMedicine before joining MaxCyte.

Doug Smith headshot

Doug Smith, PhD

SVP, Science and Innovation, SeQure DX

Douglas Smith, Ph.D., is an accomplished biotechnology leader with nearly 40 years of experience. He began his career at Genome Therapeutics Corp., where he spent 16 years in genomics and technology. He went on to hold senior roles at Agencourt Bioscience, Beckman Coulter Genomics, and Courtagen Life Sciences, specializing in bioinformatics and R&D. Since 2017, he has worked as an independent consultant and currently serves as Sr. Vice President of R&D and Chief Scientific Officer at SeQure Dx. Dr. Smith holds a B.Sc. from McGill University and a Ph.D. from Cornell University in Biochemistry and Molecular Biology.

Register below to attend this event

Popular resources

maxcyte-enables-a-cgmp-compatible-manufacturing-process-for-highly-efficient-t-cell@2x-min
application note
MaxCyte® Enables a cGMP-Compatible Manufacturing Process for Highly Efficient T Cell Engineering
Conditional-Deletion-of-Large-DNA-Fragment-in-iPSCs-by-ssODN-Mediated-Insertion-of-LoxP-Sites-without-Antibiotic-Selection-Fig-2 1
Scientific Brief
Gene Editing: Paving the Way for Accelerated Clinical Development of Adoptive Cell Therapies
Experimental-Design-hires 1
Scientific Brief
Conditional Deletion of Large DNA Fragment in iPSCs by ssODN-Mediated Insertion of LoxP Sites without Antibiotic Selection
View All Resources